scholarly article | Q13442814 |
P50 | author | David R Gandara | Q73567194 |
Timothy Synold | Q78536675 | ||
Heinz-Josef Lenz | Q89668545 | ||
P2093 | author name string | Anne Hamilton | |
Percy Ivy | |||
Heinz Josef Lenz | |||
Sridhar Mani | |||
David Gandara | |||
Sunil Sharma | |||
Martin Graham | |||
Chris H. Takimoto | |||
Ramesh K. Ramanathan | |||
Daniel Mulkerin | |||
Jeffrey Longmate | |||
James H. Doroshow | |||
Scot C. Remick | |||
P433 | issue | 4 Suppl 15 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pharmacology | Q128406 |
oncology | Q162555 | ||
oxaliplatin | Q422327 | ||
P304 | page(s) | 14-19 | |
P577 | publication date | 2003-08-01 | |
P1433 | published in | Seminars in Oncology | Q14330412 |
P1476 | title | Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group | |
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group | |||
P478 | volume | 30 |
Q33373035 | A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression |
Q35906940 | A review of oxaliplatin and its clinical use in colorectal cancer |
Q37475755 | Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction |
Q38626963 | Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer |
Q35680674 | Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer |
Q37682504 | Clinical management of inflammatory bowel disease in the organ recipient |
Q36459787 | Clinical pharmacology of cancer therapies in older adults. |
Q38241395 | Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. |
Q38101612 | Current opinion on optimal treatment for colorectal cancer. |
Q35827606 | Drug development in oncology: classical cytotoxics and molecularly targeted agents |
Q36165081 | Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies |
Q37419104 | Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer |
Q26861560 | Hepatotoxicity Secondary to Chemotherapy |
Q37126758 | Incidence and management of colorectal cancer in liver transplant recipients |
Q36788436 | Oxaliplatin in the treatment of colorectal cancer |
Q37326848 | Part I: Liver function in oncology: biochemistry and beyond |
Q37336474 | Part II: Liver function in oncology: towards safer chemotherapy use. |
Q36715263 | Pharmacokinetics of chemotherapy in the older patient. |
Q42364212 | Safe use of capecitabine-cisplatin in metastatic gastric carcinoma with severe liver dysfunction: a case report from Algeria |
Q46024262 | Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer. |
Q38866096 | The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects |
Q38030767 | Treatment decisions for elderly patients with haematological malignancies: a dilemma |